feedback

Course Director

Elizabeth A. Mittendorf, MD, PhD
Elizabeth A. Mittendorf, MD, PhD

Brigham and Women’s Hospital
Dana-Farber/Brigham and Women’s Cancer Center
Boston, Massachusetts

Faculty

Jennifer Litton
Jennifer Litton, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Heather L. McArthur
Heather L. McArthur, MD, MPH

Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC / CNE
Credit Amount:1.25 Credits
Release Date:2019-Jun-03
Expiration Date:2020-Jun-02
Estimated Time for Completion:75 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

Tremendous advances have been made in the treatment of many other subtypes of breast cancer, but treatment of triple-negative breast cancer (TNBC) has remained challenging. However, recent developments suggest that we are on the brink of a new era in TNBC therapy that now brings the novel class of cancer immunotherapies to this population of patients.

In this activity, based on a recent live satellite symposium held in Dallas, Texas during the 20th Annual Meeting of The American Society of Breast Surgeons, our expert panel discusses the biologic rationale for the use of cancer immunotherapies in breast cancer in general and TNBC specifically, as well as the evolving evidence supporting the use of immune checkpoint inhibitors in advanced/metastatic and early-stage resectable TNBC.

Additionally, the panel focuses on patient/tumor evaluation and candidate selection for immunotherapy, using current and novel biomarkers to guide clinical decisions in early-stage and advanced disease, the importance of being aware of potential immune-related adverse events and how to diagnose/manage them, and the need for close collaboration among breast surgeons, oncologists, pathologists, and other professionals involved in the management of patients with breast cancer.

Upon completion of this activity, participants will be able to:
  • Describe the biologic rationale and rational strategies for harnessing the immune system in the treatment of triple-negative breast cancer (TNBC) specifically, and in breast cancer more broadly, including combinatorial or sequential approaches with immune checkpoint inhibitors and other effective therapies (eg, chemotherapies, other immunotherapies, PARP inhibitors and other targeted agents, surgery, radiation, etc.) that may enhance immunogenicity and improve outcomes
  • Discuss biomarkers that may have utility in guiding and refining clinical decisions regarding the selection of appropriate candidates for immune-based and other therapies in TNBC, and the nuances of testing for these biomarkers in practice
  • Analyze efficacy, safety, and other key data from clinical trials assessing immunotherapy and immune-based combinations or sequential strategies with other effective treatment modalities throughout the continuum of TNBC, including metastatic, locally advanced, and early-stage resectable disease
  • Integrate immune checkpoint inhibitors and/or other effective treatment modalities into management plans of patients with TNBC based on the latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, biomarker testing results, and patient needs/preferences

Target Audience

This activity has been designed to meet the educational needs of breast surgeons, oncologists, and other professionals involved in the management of patients with breast cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC/CNE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: June 03, 2019 - June 02, 2020
Time to Complete: 75 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Other PVI associates who are in a position to have control over the content of this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE activity during the past 12 months.

The associates of the Medical Learning Institute, Inc., the accredited provider for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE activity during the past 12 months.

Course Director

Elizabeth A. Mittendorf, MD, PhD
Rob and Karen Hale Distinguished Chair in Surgical Oncology
Director of Research, Breast Surgical Oncology
Brigham and Women’s Hospital
Director, Breast Immuno-Oncology Program
Dana-Farber/Brigham and Women’s Cancer Center
Boston, Massachusetts

Elizabeth A. Mittendorf, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca/MedImmune; Celgene Corporation; Genentech, Inc.; Genomic Health, Inc.; Merck & Co., Inc.; Peregrine Pharmaceuticals, Inc.; Sellas; and TapImmune.

Elizabeth A. Mittendorf, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: immune checkpoint inhibitors and combinations.

Faculty

Jennifer Litton, MD
Associate Professor
Department of Breast Medical Oncology
Clinical Cancer Genetics
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jennifer Litton, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca and Pfizer. (All funds go directly to institution).
Grant/Research Support from AstraZeneca; EMD Serono; Genentech, Inc.; GlaxoSmithKline; MedImmune; Medivation/Pfizer; and and Novartis Pharmaceuticals Corporation. (All funds go directly to institution).
Honorarium from UpToDate.

Jennifer Litton, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: immune checkpoint inhibitors and combinations.

Heather L. McArthur, MD, MPH
Medical Director, Breast Oncology
Hematology/Oncology
Samuel Oschin Comprehensive Cancer Center
Cedars-Sinai Medical Center
Los Angeles, California

Heather L. McArthur, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol-Myers Squibb; Eli Lilly and Company; Genentech, Inc.; Genomic Health, Inc.; Immunomedics; Merck & Co., Inc.; and Pfizer Inc.

Heather L. McArthur, MD, MPH, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: immune checkpoint inhibitors and combinations.

Content Reviewers

Shaina Rozell, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, has no financial interests/relationships or affiliations in relation to this activity.

Janice Trainor-Tellier, MSN, RN, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Kristin Tomlinson, PhD
PVI, PeerView Institute for Medical Education

Kristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/MOC/CNE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Nurses

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.25 contact hour(s).

Providership


This CME/MOC/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from Merck & Co., Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC/CNE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.